Equibles does not estimate personal net worth.
Get an email with a short summary when Biogen Inc. publishes a filing, an earnings call transcript or a press release.
Get BIIB alertsAlfred Sandrock is recorded as Board Member at Voyager Therapeutics, Inc. (VYGR) since January 1, 2022 and CEO at Voyager Therapeutics, Inc. (VYGR). The newest filing on record that lists Alfred Sandrock as CEO and Board Member at Voyager Therapeutics, Inc. (VYGR) is dated April 28, 2026. The proxy statement of Voyager Therapeutics, Inc. reports total compensation of $2,508,370 for Alfred Sandrock in fiscal 2025, including a base salary of $674,903. Disclosed compensation is on record for 5 fiscal years. Alfred Sandrock has spoken on 6 earnings calls across 1 company, most recently for Voyager Therapeutics, Inc. on March 11, 2025. Voyager Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Biogen Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Voyager Therapeutics, Inc. includes Alfred Sandrock, M.D., Ph.D. (CEO and Board Member), Michael Higgins (CEO and Board Member), Nathan Jorgensen, Ph.D., M.B.A. (CFO) and 7 others.
“As Trista said, we plan to keep our remarks brief and prioritize your questions. On Slide 3, I want to remind you of why we're so excited about Voyager. Our pipeline includes four wholly owned and 13 partnered programs.”
“At Voyager, we are leveraging the power of human genetics to discover and deliver transformative medicines that address the root cause of neurological diseases.”
“At Voyager, we are leveraging the power of human genetics to discover and develop transformative medicines that address the root cause of neurological diseases.”
“I'd like to start by thanking the Voyager team for their dedication to creating transformative genetic medicines. We made tremendous progress advancing these medicines in the first quarter.”
“I'd like to start by defining Voyager's position as an emerging leader in neurogenetic medicine. First, our pipeline. We anticipate having at least four wholly owned and partnered CNS programs in the clinic by the end of 2025, with the potential to generate clinical data in 2025 and 2026.”
2022-01-01–present
Last confirmed April 28, 2026
Source not stated
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
CEO, Board Member
2022-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Voyager Therapeutics, Inc. (VYGR) | M.D., Ph.D. Chief Executive Officer, President, and Director | $674,903 | $2,508,370 |
| 2024 | Voyager Therapeutics, Inc. (VYGR) | M.D., Ph.D. Chief Executive Officer, President, and Director | $652,080 | $3,379,876 |
| 2021 | Biogen Inc. (BIIB) | Former Executive Vice President, Research & Development | $921,621 | $5,737,900 |
| 2020 | Biogen Inc. (BIIB) | Executive Vice President, Research & Development | $890,310 | $6,226,969 |
| 2019 | Biogen Inc. (BIIB) | Executive Vice President, Research & Development | $798,723 | $5,312,565 |
